Natera Statement Regarding Illumina Suit | Natera
Back to releases

Natera Statement Regarding Illumina Suit

 

March 18, 2018

We are aware that Illumina has filed suit in the Northern District of California, alleging infringement of its ‘831 library preparation patent. We had anticipated that Illumina might file this suit in response to last week’s announcement of our deal with QIAGEN. Based on our innovative technology and our knowledge of Illumina’s patents, we feel comfortable that we will prevail in any patent suit with Illumina should it proceed, and that in any event, the downside risk would not be substantial to our business. Our 10-year supply agreement with Illumina does not expire until 2026, and we do not expect this to disrupt our operations in any way. Our current plan is to maintain use of Illumina products where their costs and service are competitive for our lab.

 

Contacts at Natera, Inc.

Investor Relations

Mike Brophy, 650-249-9091 x1471

mbrophy@natera.com

Media Relations

Anna Czene, 818-731-2203

aczene@natera.com

Back to Top